Eloxatin
Advanced Lung Carcinoma
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)Phase 1Active
CC
44/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 81/ 100
Competitive context
16 Active assets in the Advanced Lung Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II Taiho Oncology, Inc. | Phase 3 | BB |
Cyclophosphamide TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Phase 2 | B |
Carboplatin SystImmune Inc. | Phase 3 | B |
Epirubicin TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Phase 2 | B |
Pembrolizumab Essen Biotech | Phase 2 | B |
View all 17 →
Same molecule, other indications
Eloxatin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →